Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis

Richardot, P.; Tabassi, N. Charni-Ben; Toh, Ling; Marotte, Hubert; Bay‐Jensen, Anne‐Christine; Miossec, Pierre; Garnero, Patrick

doi:10.1016/j.joca.2009.04.024

Cited by 17 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…Interestingly the levels of serum IIINys were also markedly elevated (+207%) in patients with RA and the IIINys epitope detected by immunohistochemistry was highly expressed by the inflammed synovial tissue. 29,30 Helix-II marker. The Helix-II is a biological marker that was initially developed to measure the degradation of the helical portion of human type II collagen.…”

Section: Conventional Biological Markers Of Joint Tissue Turnovermentioning

confidence: 99%

See 1 more Smart Citation

Soluble biological markers in osteoarthritis

Rousseau

Chapurlat

Garnero

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Conventional Biological Markers Of Joint Tissue Turnovermentioning

confidence: 99%

Soluble biological markers in osteoarthritis

Rousseau

Chapurlat

Garnero

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…The analytical gold standard for NO 2 Tyr is mass spectrometry (Tsikas and Duncan, 2014), but this is not suitable for high-throughput analysis of clinical samples. Other quantitative approaches, such as ELISA (Pirro et al, 2007;Richardot et al, 2009), liquid chromatography (Shishehbor et al, 2003;Misko et al, 2013), or high performance liquid chromatography (Kaur and Halliwell, 1994), are currently explored to detect NO 2 Tyr clinically. However, extra effort is still needed in the field to further use NO 2 Tyr as a clinical biomarker, although the current data seem extremely promising.…”

Section: B Ros-dependent Protein Modificationmentioning

confidence: 99%

On the Clinical Pharmacology of Reactive Oxygen Species

et al. 2020

View full text Add to dashboard Cite

“…In patients with joint disorder, the synovial membrane contains nitrated proteins [42]. IIINys was increased in serum from OA patients [43] and RA patients [44]. Its level was the highest in RA patients which suggests that it is related to synovial tissue inflammation [44].…”

Section: Synovial Biomarkersmentioning

confidence: 99%

Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?

Denarié

Constant

Thomas

et al. 2014

Mediators of Inflammation

View full text Add to dashboard Cite

Objective. The aim of this review is to clarify the usefulness of bone, cartilage, and synovial biomarker in the management of rheumatoid arthritis (RA) therapy in remission. Synovial Biomarkers. High MMP-3 levels are associated with joint progression in RA patients, but there is no data about their utility in clinical remission. IIINys and Glc-Gal-PYD seem to be more specific to synovium, but more studies are required. Cartilage Biomarkers. Unbalance between cartilage break-down biomarkers (urinary CTX II and COMP) and cartilage formation biomarker (PIIANP) was described. This unbalance is also associated with joint destruction and prognosis of destruction. No data are available on patients in remission. Bone Biomarkers. RA activity is correlated with an increase of bone resorption markers such as CTX I, PYD, and TRACP 5b and a decrease of bone formation markers such as OC and BALP. RA therapies seem to improve bone turnover in limiting bone resorption. There is no study about bone marker utility in remission. Conclusion. Biomarkers seem to correlate with RA activity and progression. They also could be used to manage RA therapies, but we need more data on RA remission to predict relapse.

show abstract

Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis

Abstract: Nitration of tyrosine residues of type III collagen N-telopeptide is increased in the synovial tissue of patients with knee OA. Measurements of serum IIINys level may be useful for the clinical investigation of oxidative-related alterations of synovial tissue metabolism in OA.

Cited by 17 publications

References 20 publications

Soluble biological markers in osteoarthritis

Soluble biological markers in osteoarthritis

On the Clinical Pharmacology of Reactive Oxygen Species

Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?

Contact Info

Product

Resources

About